Actinium Pharmaceuticals, Inc. 宣布，其研发的靶向放射性药物ATNM-400，在临床前研究中取得了积极进展。研究数据显示，该药物不仅在PSMA高表达的前列腺癌模型中显示出强大的抗肿瘤活性，在PSMA低表达模型中同样表现出显著疗效。这一发现具有重要意义，因为它意味着ATNM-400的潜在治疗范围可能覆盖更广泛的前列腺癌患者群体，而不受其PSMA表达水平的严格限制，有望为那些目前治疗选择有限的患者提供新的希望。
Actinium Pharmaceuticals, Inc. 宣布，其研发的靶向放射性药物ATNM-400，在临床前研究中取得了积极进展。研究数据显示，该药物不仅在PSMA高表达的前列腺癌模型中显示出强大的抗肿瘤活性，在PSMA低表达模型中同样表现出显著疗效。这一发现具有重要意义，因为它意味着ATNM-400的潜在治疗范围可能覆盖更广泛的前列腺癌患者群体，而不受其PSMA表达水平的严格限制，有望为那些目前治疗选择有限的患者提供新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.